Oxurion NV banner

Intrinsic Value

Not Available for TG40

There is not enough data to reliably calculate the intrinsic value for Oxurion NV.

Do our valuations actually work? See backtest results .

Alternatives to TG40

Fundamental Analysis

What Oxurion Does

Biotechnology Health Care

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company employs 11 full-time employees The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013.

Headquarters
Belgium BE
Employees
11
IPO date
Jul 7, 2006
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue TG40 Research

Decided on Oxurion? Get an email when TG40 reaches the price you’d buy at. Free with an account.

Other Oxurion listings

Back to Top